QMS MEDICAL ALLIED SERVICES

Mumbai, India Founded: 1994 • Age: 32 yrs Listed
Online store for medical devices, instruments, and supplies in India.

About QMS MEDICAL ALLIED SERVICES

QMS MEDICAL ALLIED SERVICES is a publicly listed company based in Mumbai (India) founded in 1994. Online store for medical devices, instruments, and supplies in India. It operates on a B2B and B2C model. The company has 83 employees. Its Indian entity Qms Medical Allied Services Limited reported revenue of β‚Ή174 Cr. QMS MEDICAL ALLIED SERVICES offers products and services including Littmann Stethoscope, Omron Blood Pressure Monitor, Q Devices Nebulizer, Tynor Heating Gel Pad, and HEINE Sphygmomanometer. Its focus areas include Health, Medical Devices, Distribution and Online Retail. Its competitors include Medikabazaar and Aknamed; 2 of its 2 listed competitors have raised funding.

Company details

Qmsmeds is an online platform based in Mumbai, India, offering a wide range of medical products including devices, instruments, and accessories. It sources from various manufacturers and sells to clinicians, distributors, and individuals through an e-commerce interface. The service includes easy ordering, multiple payment options, and doorstep delivery across the country, ensuring access to quality medical supplies for healthcare professionals.

  • Headquarters Mumbai, India
  • Employees 83
  • Stage Public
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website qmsmeds.com
  • Social Instagram
  • Legal Name Qms Medical Allied Services Limited
  • Date of Incorporation 14 Sep, 2017
  • Jurisdiction Mumbai, Maharashtra, India
Key Metrics
  • Market Cap
    ₹329 Cr

    QMSMEDI-BE · NSE

  • Share Price
    ₹170.01

    +0.05% today

  • Revenue
    ₹173 Cr

    FY 2025-26 · +10.8% YoY

  • EBITDA
    ₹26.62 Cr

    Margin 15.4%

  • Net Profit
    ₹10.07 Cr

    FY 2025-26 · -16.6% YoY

  • P/E (TTM)
    33.3x

    P/B 3.7x

  • ROE
    12.3%

    ROCE 13.9%

  • Debt / Equity
    0.69

    Interest cover 29.9x

  • Employee Count
    83

Products & Services of QMS MEDICAL ALLIED SERVICES

QMS MEDICAL ALLIED SERVICES offers a comprehensive portfolio of products and services, including Littmann Stethoscope, Omron Blood Pressure Monitor, Q Devices Nebulizer, Tynor Heating Gel Pad, and HEINE Sphygmomanometer.

Littmann Stethoscope
Medical Devices

Diagnostic tool for monitoring heart and lung sounds

Omron Blood Pressure Monitor
Medical Devices

Digital device for accurate blood pressure measurement

Q Devices Nebulizer
Medical Devices

Portable device for respiratory treatments

Tynor Heating Gel Pad
Personal Care

Therapeutic pad for pain relief and muscle support

HEINE Sphygmomanometer
Medical Instruments

Manual device for blood pressure monitoring

Board of directors of Qms Medical Allied Services Limited (QMS MEDICAL ALLIED SERVICES)

Qms Medical Allied Services Limited is the primary company behind QMS MEDICAL ALLIED SERVICES. The board of Qms Medical Allied Services Limited currently have 6 directors; the longest-serving is Mahesh Pahalraj Makhija, appointed in 2017. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Mahesh Pahalraj Makhija
DIN 02700606
Managing Director14 Sep 20179 yrs 2 moQms Medical Allied Services Limited
Niken Ravin Shah
DIN 07604022
Director11 Mar 20224 yrs 8 moQms Medical Allied Services Limited
Prajwal Jayasheela Poojari
DIN 07480513
Director15 Jun 20224 yrs 5 moQms Medical Allied Services Limited
Deena Nath Pathak
DIN 02104727
Director23 Aug 20242 yrs 2 moQms Medical Allied Services Limited
Sarita Vijay Mahajan
DIN 10841279
Director19 Nov 20241 yr 11 moQms Medical Allied Services Limited
Pranav Manhar Badheka
DIN 06460764
Director03 Sep 20262 moQms Medical Allied Services Limited

IPO & Listings of QMS MEDICAL ALLIED SERVICES

QMS MEDICAL ALLIED SERVICES is a publicly listed company on the NSE with ticker symbol QMSMEDI in India. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: QMSMEDI
  • Listed entityQms Medical Allied Services Limited

Financials of QMS MEDICAL ALLIED SERVICES

Exchange-reported figures of Qms Medical Allied Services Limited, the listed company behind QMS MEDICAL ALLIED SERVICES (NSE: QMSMEDI-BE).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹173 Cr
+10.8% YoY
EBITDA
₹26.62 Cr
+4.8% YoY
Profit After Tax
₹10.07 Cr
-16.6% YoY
Net Worth
₹104 Cr
+16.2% YoY
Total Assets
₹189 Cr
+12.8% YoY
Total Debt
₹74.48 Cr
+23.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24
Income statement
Revenue173156122
Revenue growth+10.8%+27.7%-
EBITDA26.6225.4018.34
EBITDA margin+15.4%+16.3%+15.0%
Profit before tax16.3818.6512.23
Net profit10.0712.079.00
Net profit margin+5.8%+7.7%+7.4%
EPS (β‚Ή)6.326.775.04
Balance sheet
Total assets189168113
Net worth10489.7178.51
Total debt74.4860.2834.54
Cash & bank1.201.070.31
Net working capital11394.5281.88
Cash flow
Cash from operations19.4419.171.36
Cash from investing(20.42)(45.49)(2.73)
Cash from financing1.1126.840.41
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue52.5256.8744.4237.2644.7046.5044.5843.87
Revenue growth (YoY)+17.5%+22.3%-0.4%-15.1%+20.2%+53.1%--
Other income0.220.420.220.300.220.321.090.19
EBITDA6.528.315.916.756.926.546.376.95
EBITDA margin+12.4%+14.6%+13.3%+18.1%+15.5%+14.1%+14.3%+15.8%
Depreciation1.601.471.391.020.940.931.360.86
Interest1.861.712.081.751.361.441.411.31
Profit before tax3.285.552.664.284.844.494.694.97
Tax0.841.590.781.101.271.331.091.50
Net profit2.443.961.883.183.573.163.603.47
EPS (β‚Ή)1.262.050.971.241.712.201.871.63
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue15214512210414612272.74
Revenue growth+5.1%+18.6%+17.4%-28.9%+19.9%+67.8%-
EBITDA21.0823.3318.3411.3316.6416.999.60
EBITDA margin+13.8%+16.1%+15.0%+10.9%+11.4%+13.9%+13.2%
Profit before tax9.3114.4312.238.7114.4614.908.72
Net profit6.5910.429.006.389.6910.916.32
Net profit margin+4.3%+7.2%+7.4%+6.1%+6.6%+8.9%+8.7%
EPS (β‚Ή)3.515.845.043.5728.4029.0221.00
Balance sheet
Total assets19616611396.0163.0139.9321.01
Net worth10488.0478.5170.4031.0320.329.41
Total debt90.9277.252.3725.5231.9719.6011.60
Cash & bank0.110.390.312.372.161.380.66
Net working capital10388.0881.8865.6054.8529.4017.58
Cash flow
Cash from operations18.7726.091.36(7.54)(1.72)1.884.18
Cash from investing(18.27)(48.90)(1.78)(25.10)2.37(7.84)(3.66)
Cash from financing(0.78)22.88(1.07)31.740.136.690.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue50.9452.3439.1929.5441.2542.3242.3839.38
Revenue growth (YoY)+23.5%+23.7%-7.5%-25.0%+26.0%+39.4%--
Other income0.080.250.070.130.000.150.130.12
Total expenses44.6545.3434.8125.7735.1235.9934.5634.05
EBITDA6.297.004.383.776.136.337.825.33
EBITDA margin+12.3%+13.4%+11.2%+12.8%+14.9%+15.0%+18.5%+13.5%
Depreciation1.431.311.220.920.830.830.900.91
Interest2.212.052.382.061.731.772.731.31
Profit before tax2.733.890.850.923.573.884.323.23
Tax0.691.220.240.340.931.201.260.89

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 18 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue52.5256.8744.4237.2644.7046.5044.5843.87
Revenue growth (YoY)+17.5%+22.3%-0.4%-15.1%+20.2%+53.1%--
Other income0.220.420.220.300.220.321.090.19
EBITDA6.528.315.916.756.926.546.376.95
EBITDA margin+12.4%+14.6%+13.3%+18.1%+15.5%+14.1%+14.3%+15.8%
Depreciation1.601.471.391.020.940.931.360.86
Interest1.861.712.081.751.361.441.411.31
Profit before tax3.285.552.664.284.844.494.694.97
Tax0.841.590.781.101.271.331.091.50
Net profit2.443.961.883.183.573.163.603.47
EPS (β‚Ή)1.262.050.971.241.712.201.871.63
ParticularsFY 2025-26FY 2024-25FY 2023-24
Revenue173156122
Revenue growth+10.8%+27.7%-
Other income1.061.720.46
Total expenses146131104
Employee cost0.007.543.67
EBITDA26.6225.4018.34
EBITDA margin+15.4%+16.3%+15.0%
Depreciation4.613.833.44
Interest6.694.643.13
Profit before tax16.3818.6512.23
Tax4.514.963.23
Net profit10.0712.079.00
Net profit margin+5.8%+7.7%+7.4%
EPS (β‚Ή)6.326.775.04
ParticularsFY 2025-26FY 2024-25FY 2023-24
Equity & liabilities
Share capital19.3417.8517.85
Reserves & surplus84.8671.8660.66
Shareholders' funds (net worth)10489.7178.51
Minority interest9.7717.390.00
Secured loans69.0154.8233.46
Unsecured loans5.475.461.08
Total debt74.4860.2834.54
Total liabilities189168113
Assets
Gross block72.2566.2130.03
Net block54.6252.4223.58
Capital work in progress2.833.192.06
Investments5.463.232.11
Inventories45.9239.3337.58
Sundry debtors67.3257.9341.39
Cash & bank balances1.201.070.31
Loans & advances22.1218.4824.39
Total current assets137117104
Total current liabilities23.7522.2921.79
Net working capital11394.5281.88
Total assets189168113
ParticularsFY 2025-26FY 2024-25FY 2023-24
Opening cash1.060.311.27
Net cash from operating activities19.4419.171.36
Net cash from investing activities(20.42)(45.49)(2.73)
Net cash from financing activities1.1126.840.41
Net change in cash0.130.52(0.96)
Closing cash1.201.070.31
ParticularsFY 2025-26FY 2024-25FY 2023-24
Growth
Sales growth+10.8%+27.7%-
EBITDA growth+4.8%+38.5%-
PBT growth-11.9%+52.6%+9997.0%
Net income growth-16.6%+34.1%-
Profitability & leverage
Net income margin+6.9%+8.8%+7.4%
Return on capital employed+14.0%+17.7%+13.6%
Return on net worth+12.3%+16.3%+11.5%
Debt / equity0.690.560.44
Long-term debt / equity0.080.070.03
Interest cover29.8521.5021.01
Efficiency & per share
Fixed asset turnover2.503.244.07
Inventory turnover4.064.063.25
Debtors turnover2.763.142.95
EPS (β‚Ή)5.246.775.04
Dividend per share (β‚Ή)0.500.500.00
Book value per share (β‚Ή)53.8850.2643.99
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue50.9452.3439.1929.5441.2542.3242.3839.38
Revenue growth (YoY)+23.5%+23.7%-7.5%-25.0%+26.0%+39.4%--
Other income0.080.250.070.130.000.150.130.12
Total expenses44.6545.3434.8125.7735.1235.9934.5634.05
EBITDA6.297.004.383.776.136.337.825.33
EBITDA margin+12.3%+13.4%+11.2%+12.8%+14.9%+15.0%+18.5%+13.5%
Depreciation1.431.311.220.920.830.830.900.91
Interest2.212.052.382.061.731.772.731.31
Profit before tax2.733.890.850.923.573.884.323.23
Tax0.691.220.240.340.931.201.260.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue15214512210414612272.74
Revenue growth+5.1%+18.6%+17.4%-28.9%+19.9%+67.8%-
Other income0.360.460.460.741.420.060.04
Total expenses13112210492.7113010563.14
Employee cost0.006.003.672.613.831.560.92
EBITDA21.0823.3318.3411.3316.6416.999.60
EBITDA margin+13.8%+16.1%+15.0%+10.9%+11.4%+13.9%+13.2%
Depreciation4.123.403.441.071.160.740.36
Interest8.015.963.132.292.441.410.56
Profit before tax9.3114.4312.238.7114.4614.908.72
Tax2.724.003.232.333.773.992.40
Net profit6.5910.429.006.389.6910.916.32
Net profit margin+4.3%+7.2%+7.4%+6.1%+6.6%+8.9%+8.7%
EPS (β‚Ή)3.515.845.043.5728.4029.0221.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital19.3417.8517.8517.853.763.763.01
Reserves & surplus84.8870.1960.6652.5527.2716.566.40
Shareholders' funds (net worth)10488.0478.5170.4031.0320.329.41
Secured loans85.4571.790.0025.5231.3818.058.99
Unsecured loans5.475.462.370.000.591.552.61
Total debt90.9277.252.3725.5231.9719.6011.60
Total liabilities19616611396.0163.0139.9321.01
Assets
Gross block37.9032.0730.0328.379.9111.303.63
Net block24.6522.3323.5825.367.9710.173.24
Capital work in progress2.642.932.061.150.000.000.00
Investments63.0948.332.110.000.000.000.00
Inventories45.9239.2837.5829.9324.2520.3115.69
Sundry debtors59.1753.8241.3939.0442.0422.9811.21
Cash & bank balances0.110.390.312.372.161.380.66
Loans & advances22.1917.9924.3915.595.625.122.49
Total current assets12711110486.9374.0749.7930.05
Total current liabilities24.2423.4021.7921.3319.2220.3912.47
Net working capital10388.0881.8865.6054.8529.4017.58
Total assets19616611396.0163.0139.9321.01
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.380.311.272.161.380.660.14
Net cash from operating activities18.7726.091.36(7.54)(1.72)1.884.18
Net cash from investing activities(18.27)(48.90)(1.78)(25.10)2.37(7.84)(3.66)
Net cash from financing activities(0.78)22.88(1.07)31.740.136.690.00
Net change in cash(0.28)0.07(1.48)(0.90)0.780.730.52
Closing cash0.110.390.312.372.161.380.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.1%+18.6%+17.4%-28.9%+19.9%+67.8%-
EBITDA growth-9.6%+27.2%+61.9%-31.9%-2.1%+77.0%-
PBT growth-34.5%+17.9%+40.4%-39.8%-3.0%+70.9%+99.1%
Net income growth-36.8%+15.8%+41.1%-34.2%-11.2%+72.6%-
Revenue CAGR (3Y)+13.5%-0.3%+0.0%+12.7%+41.3%+1051.1%-
EBITDA CAGR (3Y)+21.9%+11.9%+2.6%+5.7%+52.9%+1093.3%-
Profitability & leverage
Net income margin+4.4%+7.2%+7.4%+6.1%+7.3%+8.9%+8.7%
Return on capital employed+9.6%+14.6%+14.7%+13.8%+32.8%+53.6%+64.8%
Return on net worth+7.0%+12.5%+12.1%+12.6%+41.6%+73.5%+101.2%
Debt / equity0.870.480.190.571.001.051.29
Long-term debt / equity0.260.170.030.030.040.000.00
Interest cover46.4429.9221.0122.3215.768.686.06
Efficiency & per share
Fixed asset turnover4.354.674.185.4413.8016.3538.49
Inventory turnover3.583.773.623.846.576.785.90
Debtors turnover2.703.043.042.574.507.147.57
EPS (β‚Ή)3.465.845.043.5728.4029.0221.00
Dividend per share (β‚Ή)0.500.500.500.000.000.000.00
Book value per share (β‚Ή)53.8949.3243.9939.4482.4854.0231.25

Competitors of QMS MEDICAL ALLIED SERVICES

QMS MEDICAL ALLIED SERVICES has 2 listed competitors in our database, 2 of them funded. They include Medikabazaar and Aknamed.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
medikabazaar.com2014Mumbai, India$184.89M547
Online marketplace for medical supplies, equipment, and devices catering to healthcare providers
aknamed.com2018Gurugram, India$21.85M246
Cloud and AI-based material management software for hospitals is offered.
Premium access

Detailed competitors of QMS MEDICAL ALLIED SERVICES

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Qms Medical Allied Services

Premium access

Complete news archive for QMS MEDICAL ALLIED SERVICES

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about QMS MEDICAL ALLIED SERVICES

QMS MEDICAL ALLIED SERVICES was founded in 1994.

QMS MEDICAL ALLIED SERVICES is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

QMS MEDICAL ALLIED SERVICES has 83 employees.

The primary company behind QMS MEDICAL ALLIED SERVICES, Qms Medical Allied Services Limited, reported revenue of β‚Ή174 Cr for FY 2026, up 11% year on year.

Qmsmeds is an online platform based in Mumbai, India, offering a wide range of medical products including devices, instruments, and accessories. It sources from various manufacturers and sells to clinicians, distributors, and individuals through an e-commerce interface. The service includes easy ordering, multiple payment options, and doorstep delivery across the country, ensuring access to quality medical supplies for healthcare professionals.

QMS MEDICAL ALLIED SERVICES's top competitors include Medikabazaar and Aknamed.

QMS MEDICAL ALLIED SERVICES offers Littmann Stethoscope, Omron Blood Pressure Monitor, Q Devices Nebulizer, Tynor Heating Gel Pad, and HEINE Sphygmomanometer.

Yes, QMS MEDICAL ALLIED SERVICES is publicly traded on NSE under the ticker symbol QMSMEDI.

QMS MEDICAL ALLIED SERVICES operates through Qms Medical Allied Services Limited.

The legal entities of QMS MEDICAL ALLIED SERVICES currently have 8 directors, including Prajwal Jayasheela Poojari, Niken Ravin Shah, Mahesh Pahalraj Makhija and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available